Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
2.
Ecancermedicalscience ; 14: ed94, 2020.
Article in English | MEDLINE | ID: mdl-32153657

ABSTRACT

Advances in cancer immunotherapy witnessed over the last decade with the licensing of numerous immune checkpoint inhibitors have greatly increased the application of this approach to treating advanced cancers. As a result, the number of health care professionals involved in the care of patients receiving immunotherapy treatments has grown. While the benefits can be significant, not all patients will experience them and toxicity can profound. elearning tools can help increase knowledge around the mechanisms, benefits and side effects of immunotherapies among clinical staff supporting patients undertaking such treatments.

3.
J Med Virol ; 84(11): 1737-43, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22997076

ABSTRACT

Injecting drug users are the principal at risk group for blood borne viruses. The aim was to assess the feasibility of screening substance misusers for blood borne viruses, and to offer appropriate vaccinations/referral to hepatology services. This was a nurse led prospective 6-month study based at a large Substance Misuse Service in south east England. Of the 196 consecutive individuals assessed, 81 were eligible for HBV immunization of whom only 33.3% completed a vaccination course. Prevalence of positive serological markers were: anti-HBc 14.4%, HBsAg 1.5%, and HCV antibody 37.9%. Compared to men, women were more likely to accept blood borne virus testing (83.3% vs. 62.3%), have ever injected (89.6% vs. 76.3%), overdose (54.2% vs. 23.6%), be anti-HBc positive (27.5% vs. 8.8%), drink alcohol above national recommended guidelines (41.7% vs. 25.7%), and have a positive HCV serology (55% vs. 30.4%) (P ≤ 0.05 for all). Of the 73 individuals identified with a positive HBsAg and or HCV antibody, only 14 (19.1%) were known to hepatology services and 8 (20%) of those eligible subsequently accepted a specialist referral. In conclusion, serological markers for blood borne viruses remain high in substance misusers (anti-HBc 14.4%, HCV antibody 37.9%), with women more likely to be positive. Overall, only 33.3% and 20%, respectively, complete HBV vaccination and accept a hepatology referral. A multidisciplinary approach is paramount to address both the blood borne viruses and the substance misuse and realignment of hepatitis services to Substance Misuse Services may offer such a strategy.


Subject(s)
Drug Users , Hepatitis B/epidemiology , Hepatitis C/epidemiology , Adult , England/epidemiology , Female , Hepatitis B/immunology , Hepatitis B Antibodies/blood , Hepatitis B Surface Antigens/blood , Hepatitis B Vaccines/administration & dosage , Hepatitis C/immunology , Hepatitis C Antibodies/blood , Humans , Male , Middle Aged , Patient Acceptance of Health Care/statistics & numerical data , Prospective Studies , Seroepidemiologic Studies , Sex Factors , Substance Abuse, Intravenous/complications , Vaccination/statistics & numerical data
4.
Appl Opt ; 46(8): 1244-50, 2007 Mar 10.
Article in English | MEDLINE | ID: mdl-17318244

ABSTRACT

Volumetric 3D displays are frequently purported to lack the ability to reconstruct scenes with viewer-position-dependent effects such as occlusion. To counter these claims, a swept-screen 198-view horizontal-parallax-only 3D display is reported here that is capable of viewer-position-dependent effects. A digital projector illuminates a rotating vertical diffuser with a series of multiperspective 768 x 768 pixel renderings of a 3D scene. Evidence of near-far object occlusion is reported. The aggregate virtual screen surface for a stationary observer is described, as are guidelines to construct a full-parallax system and the theoretical ability of the present system to project imagery outside of the volume swept by the screen.

5.
Ear Nose Throat J ; 85(8): 494, 496, 498, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16999055

ABSTRACT

We conducted a retrospective study to evaluate the long-term effectiveness of gentamicin applied directly to the round window membrane via the Silverstein MicroWick system in patients with definite or probable Ménière's disease. The study population was made up of 69 patients who had received 3 drops of gentamicin 10 mg/ml three times daily; the duration of treatment was guided by objective data obtained from weekly electronystagmography and audiometry. Relief of vertigo was assessed by chart review and telephone interviews. After a minimum follow-up of 24 months, we found that vertiginous symptoms remained controlled in 53 patients (76.8%) after one or more courses of drug therapy. A single course of treatmentwas successful in 41 patients (59.4%). We conclude that long-term control of vertigo can be achieved inpatients with Ménère's disease by direct application of gentamicin to the round window membrane via the Silverstein MicroWick. This minimally invasive self-treatment technique was well tolerated and free of long-term complications.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Drug Delivery Systems , Gentamicins/administration & dosage , Meniere Disease/drug therapy , Treatment Outcome , Vertigo/drug therapy , Administration, Topical , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Female , Gentamicins/therapeutic use , Humans , Male , Meniere Disease/complications , Middle Aged , Retrospective Studies , Time Factors , Tympanic Membrane/drug effects , Vertigo/etiology
6.
Ear Nose Throat J ; 85(7): 427-30, 442, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16909811

ABSTRACT

We conducted a study of 91 patients with severe-to-profound asymmetric hearing loss to assess their satisfaction with digital contralateral routing of signal (CROS) or bilateral contralateral routing of signal (BiCROS) hearing aids, Satisfaction was evaluated on the basis of the number of patients who elected to purchase their hearing aid following a free 30-day trial and on the results of a subsequent 8-question survey. We found that overall patient satisfaction was generally high. At the end of the 30-day trial, 66 of the 91 patients (72.5%) elected to keep their CROS or BiCROS device, a percentage that is far greater than the acceptance rates of 10 to 20% that had been previously reported with older models of the CROS and BiCROS devices. According to the survey responses, those who kept their devices gave them an overall rating of 3.4 on a scale of 1 (very dissatisfied) to 5 (very satisfied); those who returned their devices gave them an overall rating of 1.9.


Subject(s)
Hearing Aids/psychology , Hearing Loss/rehabilitation , Patient Satisfaction , Adult , Aged , Aged, 80 and over , Equipment Design , Female , Humans , Male , Middle Aged , Severity of Illness Index , Surveys and Questionnaires , Treatment Outcome
7.
Dysphagia ; 21(1): 66-74, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16544094

ABSTRACT

The purposes of this study were to (1) evaluate swallowing function using both subjective and objective measures in patients treated nonsurgically for stages III and IV laryngeal squamous cell carcinoma, (2) assess the effect of time from treatment completion on swallowing function, and (3) assess sequelae associated with modality of treatment. To achieve these objectives, a retrospective study of 14 patients was conducted. Fiberoptic endoscopic evaluation of swallowing (FEES) was performed and evaluated by three independent judges for seven functional criteria: standing secretions, valleculae spillage, valleculae residue, postcricoid residue, laryngeal penetration, aspiration, and cough. Patient interviews were performed to establish patient perception of swallowing and his/her current posttreatment diet. Results revealed that each patient exhibited swallowing abnormalities in at least one of the seven objective functional categories studied. Ten patients suffered from variable degrees of dysphagia, ranging from mild to severe, on all measures. No significant differences were noted between those patients with less than or greater than 12 months posttreatment. Common treatment sequelae included PEG tube placement for nutritional supplementation, tracheostomy placement for airway security and/or pulmonary toilet, repeated episodes of aspiration pneumonia requiring hospital admission, and radiation-induced oropharyngeal stricture. Further studies using subjective and objective swallowing function measures for patients treated with alternative chemoradiation regimens versus surgery (with or without adjuvant therapies) for advanced stage laryngeal cancer are needed.


Subject(s)
Carcinoma, Squamous Cell/therapy , Deglutition Disorders/etiology , Deglutition , Laryngeal Neoplasms/therapy , Aged , Carcinoma, Squamous Cell/complications , Deglutition Disorders/therapy , Female , Humans , Laryngeal Neoplasms/complications , Male , Middle Aged , Retrospective Studies , Treatment Outcome
9.
Otolaryngol Head Neck Surg ; 129(3): 199-203, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12958567

ABSTRACT

OBJECTIVE: We sought to determine the effect of montelukast, a leukotriene receptor antagonist, on intradermal skin testing. Study design and setting We conducted a prospective, randomized, double-blind, placebo-controlled study in a university setting. METHODS: After a 1-week washout of allergy pharmacotherapy, intradermal skin testing was performed on 23 atopic subjects. Whealing size was measured 20 minutes after injection. Subjects then began a 1-week regimen of daily loratadine, montelukast, or placebo. At 1 week, subjects again underwent intradermal skin testing. The change in wheal size was then calculated from baseline. RESULTS: A significant difference (P < 0.05) between the montelukast and loratadine groups in suppression of intradermal whealing at 1 week was observed. No significant difference was noted between the montelukast and placebo subjects. CONCLUSIONS: Montelukast demonstrated no significant suppression of skin whealing after antigen challenge over placebo. SIGNIFICANCE: Montelukast does not need to be discontinued before intradermal allergy testing.


Subject(s)
Acetates/therapeutic use , Hypersensitivity, Immediate/drug therapy , Hypersensitivity, Immediate/etiology , Leukotriene Antagonists/therapeutic use , Quinolines/therapeutic use , Rhinitis, Allergic, Seasonal/diagnosis , Skin Tests/adverse effects , Acetates/administration & dosage , Adolescent , Adult , Aged , Anti-Allergic Agents/therapeutic use , Candida albicans/immunology , Cyclopropanes , Double-Blind Method , Female , Follow-Up Studies , Histamine/immunology , Humans , Hypersensitivity, Immediate/immunology , Injections, Intradermal , Leukotriene Antagonists/administration & dosage , Loratadine/therapeutic use , Male , Middle Aged , Prospective Studies , Quinolines/administration & dosage , Sulfides
10.
Laryngoscope ; 113(4): 720-8, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12671435

ABSTRACT

OBJECTIVES: Objectives were 1) to provide comprehensive evaluations of functional outcomes using perceptual and objective measures of patients treated nonsurgically for stages III and IV laryngeal squamous cell carcinoma and 2) to propose a standard battery of tests that can be used for appraising functional outcomes in this patient population. STUDY DESIGN: Retrospective study of 14 patients. METHODS: Perceptual measures of voice were obtained using blinded expert listener impression ratings and a validated quality of life questionnaire (Voice Handicap Index). Objective data included acoustic, speech aerodynamic, and videostroboscopic evaluations. Patients were also assessed relative to stability of the airway, secretion control, and ability to tolerate oral diet without aspiration symptoms. RESULTS: Patients demonstrated functional but abnormal voice, speech, and swallowing abilities after treatment. More specifically, patients were judged to have moderately deviant biomechanical findings on videostroboscopy that did not improve with longer time intervals after treatment. These findings helped to explain the moderately abnormal acoustic and aerodynamic measurements revealing high values for jitter, shimmer, noise, airflow, glottal resistance, and subglottal pressures and substantially lower than normal maximum phonation times. Expert listeners were in agreement with the objective findings. However, patients rated themselves as only mildly impaired with regard to the emotional, physical, and functional handicapping effects of treatment, difficulties that were judged to improve with longer time intervals after treatment. Swallowing function showed a trend toward improvement for patients with time intervals of more than 12 months since completion of therapy. CONCLUSIONS: Patients demonstrated variable degrees of laryngeal dysfunction as evidenced by perceptual and objective measures. Patients rated themselves to be only mildly handicapped with regard to voice quality. A methodology and battery of tests are proposed to help standardize outcome data collection for this patient population.


Subject(s)
Carcinoma, Squamous Cell/therapy , Laryngeal Neoplasms/therapy , Quality of Life , Aged , Carcinoma, Squamous Cell/complications , Deglutition Disorders/diagnosis , Deglutition Disorders/etiology , Female , Humans , Laryngeal Neoplasms/complications , Laryngeal Neoplasms/physiopathology , Male , Middle Aged , Neoplasm Staging , Retrospective Studies , Severity of Illness Index , Speech Acoustics , Surveys and Questionnaires , Voice Disorders/diagnosis , Voice Disorders/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...